- Home
- ANVS vs ATNM Comparison
ANVS vs ATNM Comparison
Compare ANVS & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- ATNM
- Stock Information
- Founded
- ANVS 2008
- ATNM 2000
- Country
- ANVS United States
- ATNM United States
- Employees
- ANVS N/A
- ATNM N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- ATNM Health Care
- Exchange
- ANVS Nasdaq
- ATNM Nasdaq
- Market Cap
- ANVS 55.5M
- ATNM 49.0M
- IPO Year
- ANVS 2020
- ATNM N/A
- Fundamental
- Price
- ANVS $2.74
- ATNM $1.69
- Analyst Decision
- ANVS Strong Buy
- ATNM Strong Buy
- Analyst Count
- ANVS 4
- ATNM 2
- Target Price
- ANVS $18.00
- ATNM $4.50
- AVG Volume (30 Days)
- ANVS 277.6K
- ATNM 213.8K
- Earning Date
- ANVS 08-12-2025
- ATNM 08-08-2025
- Dividend Yield
- ANVS N/A
- ATNM N/A
- EPS Growth
- ANVS N/A
- ATNM N/A
- EPS
- ANVS N/A
- ATNM N/A
- Revenue
- ANVS N/A
- ATNM N/A
- Revenue This Year
- ANVS N/A
- ATNM N/A
- Revenue Next Year
- ANVS N/A
- ATNM N/A
- P/E Ratio
- ANVS N/A
- ATNM N/A
- Revenue Growth
- ANVS N/A
- ATNM N/A
- 52 Week Low
- ANVS $1.11
- ATNM $1.03
- 52 Week High
- ANVS $10.54
- ATNM $2.41
- Technical
- Relative Strength Index (RSI)
- ANVS 52.55
- ATNM 55.82
- Support Level
- ANVS $2.58
- ATNM $1.39
- Resistance Level
- ANVS $2.94
- ATNM $1.89
- Average True Range (ATR)
- ANVS 0.21
- ATNM 0.12
- MACD
- ANVS -0.00
- ATNM -0.00
- Stochastic Oscillator
- ANVS 64.41
- ATNM 81.08
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.